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Abstract
IMPORTANCE Male sex is associated with severe COVID-19. It is not known whether the risk of
hospitalization differs between men with hypogonadism, men with eugonadism, and those receiving
testosterone therapy (TTh).

Key Points
Question Is male hypogonadism a risk
factor for hospitalization for COVID-19?
Findings In this cohort study of 723
men, those with hypogonadism had

OBJECTIVE To compare COVID-19 hospitalization rates for men with hypogonadism who were not

significantly higher odds than men with

receiving TTh, men with eugonadism, and men receiving TTh.

eugonadism of being hospitalized,
independent of other known risk factors

DESIGN, SETTING, AND PARTICIPANTS This cohort study was conducted in 2 large academic

for COVID-19–related hospitalization.

health systems in St Louis, Missouri, among 723 men with a history of COVID-19 who had

Men receiving testosterone therapy had

testosterone concentrations measured between January 1, 2017, and December 31, 2021.

a similar risk of hospitalization as men
with eugonadism.

EXPOSURES The primary exposure was gonadal status (hypogonadism, eugonadism, and TTh).
Hypogonadism was defined as a total testosterone concentration below the limit of normal provided
by the laboratory (which varied from 175 to 300 ng/dL [to convert to nanomoles per liter, multiply
by 0.0347]).

Meaning This study suggests that men
with hypogonadism are more likely to
be hospitalized after COVID-19 infection
compared with men with eugonadism
and men receiving adequate

MAIN OUTCOMES AND MEASURES The primary outcome was rate of hospitalization for COVID-19.

testosterone therapy.

Statistical adjustments were made for group differences in age, body mass index, race and ethnicity,
immunosuppression, and comorbid conditions.
RESULTS Of the 723 study participants (mean [SD] age, 55 [14] years; mean [SD] body mass index,
33.5 [7.3]), 116 men had hypogonadism, 427 had eugonadism, and 180 were receiving TTh. Men with

+ Supplemental content
Author affiliations and article information are
listed at the end of this article.

hypogonadism were more likely than men with eugonadism to be hospitalized with COVID-19 (52 of
116 [45%] vs 53 of 427 [12%]; P < .001). After multivariable adjustment, men with hypogonadism had
higher odds than men with eugonadism of being hospitalized (odds ratio, 2.4; 95% CI, 1.4-4.4;
P < .003). Men receiving TTh had a similar risk of hospitalization as men with eugonadism (odds
ratio, 1.3; 95% CI, 0.7-2.3; P = .35). Men receiving inadequate TTh (defined as subnormal
testosterone concentrations while receiving TTh) had higher odds of hospitalization compared with
men who had normal testosterone concentrations while receiving TTh (multivariable adjusted odds
ratio, 3.5; 95% CI, 1.5-8.6; P = .003).
CONCLUSIONS AND RELEVANCE This study suggests that men with hypogonadism were more
likely to be hospitalized after COVID-19 infection compared with those with eugonadism,
independent of other known risk factors. This increased risk was not observed among men receiving
adequate TTh. Screening and appropriate therapy for hypogonadism need to be evaluated as a
strategy to prevent severe COVID-19 outcomes among men.
JAMA Network Open. 2022;5(9):e2229747. doi:10.1001/jamanetworkopen.2022.29747
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Introduction
The COVID-19 pandemic has exacted a heavy toll on public health. Epidemiologic data have identified
certain characteristics that are associated with adverse outcomes, including advanced age, obesity,
and systemic diseases, particularly diabetes, hypertension, chronic lung disease, and cardiovascular
and cerebrovascular diseases.1 In addition, patients hospitalized for COVID-19 are more likely to be
men than women.2 Therefore, it was presumed that testosterone is a risk factor for severe COVID-19
and that estrogen may be protective against COVID-19.3 However, not all men have similar
testosterone concentrations.4,5 Men’s testosterone concentrations decrease continuously by 1% to
2% per year, starting after the third decade of life.6-8 In addition, obesity, metabolic syndrome, and
chronic illnesses, such as type 2 diabetes, kidney insufficiency, and chronic lung disease, are
associated with lower serum testosterone concentrations among men.4,9,10 Thus, aging and the
presence of comorbid conditions, which are risk factors for hospitalization for COVID-19, are also
associated with hypogonadism, which raises the question of whether hypogonadism is a risk factor
for COVID-19–related hospitalization among men.
Recent studies have shown that testosterone concentrations during hospitalization are lower in
men with severe COVID-19 than in men with a milder disease course.11-13 Because acute illness can
lower testosterone concentrations,14 it was not clear whether testosterone concentrations in men
with severe illness were subnormal even prior to contracting COVID-19. Men with chronically low
testosterone concentrations have decreased muscle mass and less strength, both of which
contribute to reduced lung capacity and ventilator dependence.15-17 Whether pre–COVID-19
testosterone concentrations in men are associated with the course of illness after COVID-19
remains unknown.
We reviewed the medical records of men who had a history of COVID-19 infection and had
testosterone concentrations measured in the outpatient setting (when they did not have COVID-19).
We hypothesized that men with subnormal testosterone concentrations prior to COVID-19 infection
would be more likely to require hospitalization than men with normal testosterone concentrations.
We also investigated whether testosterone therapy (TTh) modified the risk of hospitalization among
men with hypogonadism.

Methods
This retrospective cohort study was approved and a waiver of informed consent was granted by the
institutional review boards of St Louis University and Washington University in St Louis, Missouri. The
data set was deidentified after data collection, as per Health Insurance Portability and Accountability
Act Authorization per section 164.512(i) of the Privacy Rule. This study followed the Strengthening
the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.
We searched the electronic health records of 2 major health systems in St Louis, SSM and BJC
HealthCare, to identify patients who met the following criteria: men, older than 18 years of age,
history of COVID-19 infection (International Statistical Classification of Diseases and Related Health
Problems, Tenth Revision code U07.1), and had at least 1 measurement of testosterone concentration.
The study period was between January 1, 2017, and December 31, 2021, and 820 patients met the
inclusion criteria (Figure 1). The electronic health records of these patients were individually
reviewed. We excluded patients whose COVID-19 had not been documented by a positive nasal
reverse transcription–polymerase chain reaction test or who were incidentally found to be positive
for COVID-19 during screening for a planned surgical procedure or unrelated hospitalization. If
multiple testosterone measurements were available, we chose the one that was collected in an
outpatient setting prior to COVID-19 infection, in the morning (if available), and temporally closer to
the COVID-19 infection. We excluded patients whose testosterone concentrations were measured
only during an acute illness (such as hospitalization). Other exclusion criteria were (1) testosterone
concentrations measured less than 1 month after COVID-19, (2) age younger than 18 years at the time
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of testosterone measurement, and (3) transgender individuals. Testosterone concentrations prior to
January 2017 (>5 years ago) were excluded because they might not have reflected the baseline
gonadal state of the patient during the COVID-19 infection. After review of electronic health records,
97 men were found to be ineligible based on the study criteria. Thus, 723 men were included in the
final analysis.
We collected information on demographic characteristics (age, body mass index [BMI;
calculated as weight in kilograms divided by height in meters squared], and race and ethnicity),
comorbid conditions, hospitalization for COVID-19, and receipt of TTh. For inclusion in the TTh group,
a patient should have been receiving TTh for at least 6 months preceding the COVID-19 infection.
Patients were presumed to be immunosuppressed if they had an organ transplant or were receiving
supraphysiological doses of corticosteroids or taking immunosuppressive medications for other
conditions, such as multiple sclerosis, inflammatory bowel disease, rheumatologic diseases, or
malignant neoplasm. For hospitalized patients, we collected information on the duration of
hospitalization, intensive care unit (ICU) admission, use of a ventilator, and number of days on a
ventilator. We also collected data on mortality and assessed whether the death was associated with
COVID-19. All of the medical records with ambiguity regarding the assessment of data were audited
by the first author (S.D.).
Outpatient testosterone measurements were ordered owing to symptoms suggestive of
hypogonadism. Fatigue was the most common symptom (present in 43% of patients [311 of 723]),
followed by erectile dysfunction (30% [217 of 723]). Other reasons included decreased libido (8%
[58 of 723]), gynecomastia (5% [39 of 723]), low mood (4% [29 of 723]), opiate use (3% [24 of 723]),
pituitary adenoma (3% [23 of 723]), and obesity (3% [22 of 723]). The measurements were
performed using immunoassays (for 61% of patients [441 of 723]) or by the criterion standard
method, liquid chromatography tandem mass spectrometry (for 39% of patients [282 of 723]) by
commercial laboratories. The lower limit of normal for testosterone concentrations in the
laboratories varied between 175 and 300 ng/dL (to convert to nanomoles per liter, multiply by
0.0347). The upper limit ranged from 716 to 1100 ng/dL. We defined hypogonadism as a total
testosterone concentration below the lower limit of normal in the reference range provided by the
laboratory.

Figure 1. Study Sample and Group Allotment According to Study Inclusion and Exclusion Criteria
820 Men aged >18 y with a history of COVID-19 infection
97 Excluded
26 Did not have documented COVID-19 by
nasal RT-PCR
12 Incidentally found to be positive
for COVID-19 during unrelated
hospitalization
18 Testosterone was measured within 1 mo
after COVID-19
16 Testosterone was measured before 2017
3 Aged <18 y at the time of testosterone
treatment
22 Transgender individuals
723 Included in analysis

543 Not receiving testosterone therapy

116 Hypogonadal

180 Receiving testosterone therapy

427 Eugonadal
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Statistical Analysis
The primary exposure of the study was the gonadal status (hypogonadism, eugonadism, and TTh),
and the primary outcome was hospitalization for COVID-19. Statistical adjustments were made for
group differences in age, BMI, race and ethnicity (coded as Black, White, or other [Asian, Pacific
Islander, or American Indian]), immunosuppression (yes or no), and comorbid conditions (Charlson
Comorbidity Index [CCI]). Racial disparities have been noted in outcomes of COVID-19. Hence, we
included race and ethnicity as a covariate in our analysis. The CCI is a validated method to assess
significant medical comorbidity.18 Continuous variables are presented as either mean (SD) values or
median (IQR) values, depending on the distribution of values. Testosterone concentrations were not
normally distributed and were log-transformed to conduct parametric tests. All tests were performed
using SPSS software, version 27 (SPSS Inc). Group comparisons were performed by t tests, analysis
of variance (with Hochberg post hoc analyses), Mann-Whitney rank sum tests, χ2 tests, and Fisher
exact tests as appropriate. Multivariable logistic regression analyses are presented as odds ratios
(ORs [ie, exponential of the β coefficient with 95% CIs and P values]). Reported P values are 2-sided
and considered statistically significant at P < .05. Our study had 90% power to detect a 15%
difference in hospitalization rates between the group with eugonadism and the group with
hypogonadism.

Results
The mean (SD) age of the 723 participants was 55 (14) years, the mean (SD) BMI was 33.5 (7.3), 116
men had hypogonadism, 427 had eugonadism, and 180 were receiving TTh. Testosterone
concentrations were measured prior to COVID-19 in 73% of patients (525 of 723). The median time
between the testosterone measurement and COVID-19 infection was 7 months (IQR, 3-16 months).
For 27% of patients (198 of 723), testosterone concentrations were available only after recovery
from COVID-19; the median time between COVID-19 and testosterone measurement among those
patients was 6 months (IQR, 3-9 months).
The incidences of COVID-19 infection and hospitalization are shown in eFigures 1 and 2 in the
Supplement. Overall, 134 men were hospitalized owing to COVID-19. Men who required
hospitalization were older (mean [SD] age, 62 [15] vs 53 [14] years), had more comorbid conditions
(median CCI, 2 [IQR, 0-3] vs 0 [IQR, 0-1], and were more likely to be immunosuppressed (26 of 134
[19%] vs 24 of 589 [4%]) than men who were not hospitalized (eTable in the Supplement).
As shown in Table 1, men with hypogonadism were more likely to require hospitalization than
those with eugonadism (52 of 116 [45%] vs 53 of 427 [12%]). Men receiving TTh had a risk of
hospitalization similar to those with eugonadism (29 of 180 [16%] vs 53 of 427 [12%]). Men with
hypogonadism had a higher risk of ICU admission than those with eugonadism (10 of 116 [9%] vs 13
of 427 [3%]) but a similar risk of ventilator requirement (5 of 116 [4%] vs 7 of 427 [2%]) and mortality
(5 of 116 [4%] vs 9 of 427 [2%]). However, very few men experienced these outcomes. There were
no differences among the men with hypogonadism, the men with eugonadism, and the men
receiving TTh in the median number of days spent in the hospital (6 days [IQR, 3-12 days] vs 6 days
[IQR, 3-10 days] vs 8 days [IQR, 4-13 days]), ICU (6 days [IQR, 4-24 days] vs 4 days [IQR, 2-17 days] vs
14 days [IQR, 6-17 days]), or on ventilators (14 days [IQR, 3-44 days] vs 8 days [IQR, 4-44 days] vs 12
days [IQR, 4-16 days]).
We calculated the odds ratios of hospitalization among the 3 groups after adjustment for age,
BMI, race and ethnicity, CCI, and immunosuppression rates (Table 2).19 Men with hypogonadism
were 2.4 times more likely than those with eugonadism to require hospitalization for COVID-19 in the
fully adjusted model (OR, 2.4; 95% CI, 1.4-4.4; P < .003). Men receiving TTh had a similar risk of
hospitalization as men with eugonadism (OR, 1.3; 95% CI, 0.7-2.3; P = .35). Other significant factors
associated with hospitalization in the adjusted model were age (OR, 1.03; 95% CI, 1.01-1.05; P = .02),
CCI (OR, 1.3; 95% CI, 1.1-1.5; P < .001), and immunosuppression (OR, 3.5; 95% CI, 1.5-7.8; P = .003).
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Men with hypogonadism were not more likely than those with eugonadism to require ICU admission
after multivariable adjustment (OR, 1.2; 95% CI, 0.4-3.5; P = .69).

Testosterone Concentrations and Risk of Hospitalization Among Men
With Hypogonadism and Men With Eugonadism
We compared the risk of hospitalization across the continuum of testosterone concentrations.
Hospitalization rates increased if the patient’s testosterone concentration was lower than 200 ng/dL
(Figure 2). Thirty-two men were receiving androgen deprivation therapy for prostate cancer; their
median testosterone concentration was 3.5 ng/dL (IQR, 1.5-14.8 ng/dL). Eighteen of those men
(56%) were hospitalized owing to COVID-19, and 3 men (9%) required ICU care.
Testosterone concentrations were measured before COVID-19 among 67% of men with
eugonadism (284 of 427) and 75% of men with hypogonadism (87 of 116). We considered the
possibility that COVID-19 illness may have induced a long-term change in testosterone
concentrations. Hence, we compared the ORs for hospitalization separately among patients whose
testosterone concentrations had been measured before or after COVID. The ORs were similar to the

Table 1. Demographic and Hospitalization Characteristics
Men, No. (%)
Characteristic

Hypogonadal
(n = 116)

Eugonadal
(n = 427)

Testosterone therapy
(n = 180)

P value

Age, mean (SD), y

62 (15)a,b

53 (14)

55 (12)

<.001

BMI, mean (SD)

35 (9)a

33 (7)b

35 (7)a

<.001

129 (72)

.04

b

Obesity

73 (63)

259 (61)

Testosterone, median (IQR), ng/dL

131 (18-187)a,b

381 (300-504)

396 (248-624)

<.001

Charlson comorbidity index,
median (IQR)

2 (0-3)

0 (0-1)

0 (0-2)

<.001

Diabetes

45 (39)

89 (21)

57 (32)

<.001

Immunosuppressed

19 (16)

24 (6)

7 (4)

<.001

History of cardiovascular events

24 (21)a

48 (11)

24 (13)

.03

Black

26 (22)a,b

62 (15)b

12 (7)

<.001

White

87 (75)b

353 (83)b

167 (93)

<.001

Otherc

Race and ethnicity

3 (3)

12 (3)

1 (1)

.22

Hospitalized

52 (45)a,b

53 (12)

29 (16)

<.001

ICU

10 (9)a

13 (3)

9 (5)

.03

Ventilator

5 (4)

7 (2)

6 (3)

.18

Mortality from COVID-19

5 (4)

9 (2)

3 (2)

.30

Length of stay in hospital,
median (IQR), d

6 (3-12)

6 (3-10)

8 (4-13)

.33

Length of stay in ICU,
median (IQR), d

6 (4-24)

4 (2-17)

14 (6-17)

.39

Time on ventilator, median (IQR), d

14 (3-44)

8 (4-44)

12 (4-16)

.90

Abbreviations: BMI, body mass index (calculated as
weight in kilograms divided by height in meters
squared); ICU, intensive care unit.
SI conversion factor: To convert testosterone to
nanomoles per liter, multiply by 0.0347.
a

P < .05 compared with the group with eugonadism.

b

P < .05 compared with the group receiving TTh.

c

Asian, Pacific Islander, or American Indian.

Table 2. Odds Ratios of Hospitalization Risk Among Men With Hypogonadism and Men Receiving TTh
Compared With Men With Eugonadism
Hypogonadal

TTh

Model

Eugonadal

Odds ratio
(95% CI)

P value

Odds ratio
(95% CI)

Unadjusted

1 [Reference]

5.7 (3.6-9.1)

<.001

1.4 (0.8-2.2)

.23

Adjusted for age, BMI, immunosuppression
status, race and ethnicity, and CCIa

1 [Reference]

2.4 (1.4-4.4)

<.003

1.3 (0.7-2.3)

.35

P value

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CCI, Charlson
Comorbidity Index; TTh, testosterone therapy.
a

The estimated relative risks in the fully adjusted model for the group with hypogonadism and the group receiving TTh
were 2.1 (95% CI, 1.3-3.1) and 1.3 (95% CI, 0.7-2.0), respectively, compared with the group with eugonadism. The relative
risks were derived from odds ratios.19
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overall results; the ORs for hospitalization were 2.5 (95% CI, 1.2-5.0; P = .01) among patients whose
testosterone concentrations were measured before COVID-19 and 3.6 (95% CI, 1.0-13.2; P = .051)
among patients whose testosterone concentrations had been measured after COVID-19. We also
compared the testosterone concentrations of men whose concentrations were measured before
COVID-19 (n = 371) with those after COVID-19 (n = 172). The median testosterone concentrations
were similar in both groups (before COVID-19, 325 ng/dL [IQR, 232-458 ng/dL]; after COVID-19, 366
ng/dL [IQR, 261-484 ng/dL]; P = .22 after adjustment for age, BMI, and CCI). The prevalence of
hypogonadism among men whose testosterone concentrations were measured before COVID-19
was similar to that among men whose testosterone concentrations were measured after COVID-19
(before, 86 of 371 [23%]; after, 29 of 172 [17%]; P = .08).
Testosterone concentrations were measured in the morning for 77% of men with
hypogonadism (89 of 116) and 79% of men with eugonadism (337 of 427). Among the remaining
men, testosterone concentrations had been measured only after 12 PM. Because testosterone
concentrations are lower in the evening in men owing to diurnal variation, we reanalyzed the risk of
hospitalization after eliminating the 23% of patients with hypogonadism (27 of 116) whose
testosterone concentrations were measured in the evening. Similar to the whole population, men
with hypogonadism had higher odds of hospitalization than men with eugonadism (multivariable
adjusted OR, 2.0; 95% CI, 1.0-3.8; P = .04).

Hospitalization Among Men Receiving TTh
The most frequent mode of TTh was intramuscular testosterone cypionate or enanthate injections
(69% [124 of 180]), followed by topical gels (29% [52 of 180]) and patches (2% [4 of 180]). No
patients were receiving long-acting intramuscular testosterone undecanoate, oral testosterone
undecanoate, insertable pellets, or other modalities of testosterone replacement. The median
testosterone concentration in men receiving TTh was similar to that in men with eugonadism (396
ng/dL [IQR, 248-624 ng/dL] vs 381 ng/dL [IQR, 300-504 ng/dL]) (Table 1). However, 44 of 180 men
(24%) had subnormal testosterone concentrations while receiving TTh. These men had higher odds
of hospitalization (OR, 3.5; 95% CI, 1.5-8.6; P = .003, adjusted for age, BMI, CCI, race and ethnicity,
and immunosuppression) compared with men who had normal testosterone concentrations while
receiving TTh.

Figure 2. Probability of Hospitalization Based on Testosterone Concentrations in Men With Hypogonadism
and Men With Eugonadism, After Multivariable Adjustment for Age, Body Mass Index,
Charlson Comorbidity Index, Race and Ethnicity, and Immunosuppression Status
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Discussion
We found that men with hypogonadism were 2.4 times more likely than men with eugonadism to be
hospitalized if they contracted COVID-19. This increased risk was independent of other factors that
increase the risk of hospitalization for COVID-19, such as advanced age, comorbid conditions, and
immunosuppression. This finding contrasts with a widely held notion that men are more likely than
women to be admitted owing to COVID-19 because they have higher concentrations of circulating
testosterone. On the contrary, our data suggest that male hypogonadism is a risk factor for
hospitalization for COVID-19.
A previous study measured testosterone concentrations in hospitalized men admitted with
COVID-19 and found that 89% had subnormal testosterone concentrations on admission to the
hospital.11 Men with a more severe course of COVID-19 had lower testosterone concentrations than
men with a milder course. Similar findings have been reported in studies all around the world.13,20 It is
now well established that a low testosterone concentration is a marker of severe illness after
COVID-19, presumably owing to a suppressive effect of acute illness on the hypothalamic-pituitarygonadal axis.14 However, it was not clear whether testosterone concentrations measured when the
men did not have COVID-19 had any bearing on the course of their COVID-19 illness. Our analysis
shows that long-term low testosterone concentrations may be associated with hospitalization for
COVID-19 among men. It is possible that testosterone concentrations serve as a marker for general
health. Some of the risk factors for COVID-19–related hospitalization, such as advanced age, obesity,
and comorbid conditions, are also associated with male hypogonadism.4,21 However, our results
were robust for adjustment for these covariates. Hence, it is likely that testosterone is an
independent factor associated with the course of COVID-19 illness among men. Our findings have
important implications because hypogonadism is common among men, and physicians encounter
this condition almost daily in their outpatient practice. The prevalence of hypogonadism among men
varies from 10% to 40% depending on age, BMI, and presence of comorbid conditions.5,22,23
However, hypogonadism remains undiagnosed and untreated among many men.
We also found that men receiving TTh were less likely to be hospitalized for COVID-19 than men
with hypogonadism who were not receiving TTh. The risk of hospitalization among men receiving
TTh was similar to that among men with eugonadism. This risk reduction was limited to men who
achieved normal testosterone concentrations while receiving TTh. Men receiving inadequate TTh
had a higher risk of hospitalization than those receiving adequate TTh. The reasons for inadequate
TTh were not always recorded in the medical records, but common reasons for inadequate TTh were
prescription coverage, cost of therapy, lack of refills, patient adherence to therapy, and missed clinic
appointments. The rate of inadequate TTh in our study is similar to the rates observed in other
observational studies.24-26 A large database study of 69 632 patients receiving TTh at Veterans
Health Administration clinics found that 37% had subnormal testosterone concentrations.26 These
studies found that the health benefits associated with TTh were restricted to those receiving
adequate TTh. The reduction in the hospitalization rate with TTh suggests that testosterone is not
simply a marker of chronic health. Rather, these findings suggest a mediator role for testosterone.
Men with hypogonadism have decreased muscle mass and strength, which is associated with
functional decline and repeated hospitalizations.27 TTh is known to increase muscle mass and
strength.28 Epidemiological studies have found that TTh was associated with decreased readmission
after hospitalization among elderly men.29 TTh was also associated with reduced hospitalizations
for respiratory conditions among men with chronic obstructive pulmonary disease.30 Men with
hypogonadism are in a generalized inflammatory state compared with men with eugonadism, and
TTh reduces serum inflammatory mediators and their action at the cellular level.31-33 One small study
conducted medical record reviews of 32 men receiving TTh and compared them with 63 matched
patients not receiving TTh.34 The study found similar hospitalization and ICU admission rates after
COVID-19 between the 2 groups. These results are consistent with our findings.
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SARS-CoV-2 binds to angiotensin-converting enzyme 2 receptors and undergoes S protein
priming by the type II transmembrane serine protease (TMPRSS2) to enter cells.35,36 Because
TMPRSS2 is regulated by the androgen receptor,37 it has been hypothesized that androgen depletion
or blockade can be a therapeutic strategy to minimize COVID-19 illness. Contrary to this hypothesis,
a randomized clinical trial found that androgen blockade with enzalutamide for hospitalized patients
with COVID-19 resulted in longer hospital stays and no benefit compared with standard of care.38
Epidemiological studies that evaluated the severity of COVID-19 infections in men receiving
androgen deprivation therapies have shown inconsistent results and do not support androgen
deprivation therapy as a protection against COVID-19.39 We found a high rate of hospitalization
(56%) among men receiving androgen deprivation therapies in our study. The association between
hospitalizations and testosterone concentrations appeared to be inversely linear below 200 ng/dL,
with no indication of benefit at very low testosterone concentrations.

Limitations
Our study has many limitations, including an uneven distribution of confounding variables between
groups, which required statistical adjustments. A low event rate for death, ICU care, or ventilator
therapy precluded assessment of hypogonadism as a risk factor for severe COVID-19. Also, because
most hospitalizations were during the first year of the pandemic, when COVID-19 vaccines were not
available (eFigure 2 in the Supplement), it is unclear whether the findings apply to patients who are
fully vaccinated. The decreasing prevalence of COVID-19 and the widespread availability of vaccines
imply that a prospective study to evaluate the association of hypogonadism and TTh with the natural
course of COVID-19 illness may not be feasible, unless a new vaccine-resistant variant of COVID-19
were to emerge. Our retrospective study, therefore, provides insights to explore the role of
testosterone in other acute respiratory illnesses. Testosterone concentrations were not available
prior to COVID-19 for one-third of the men with hypogonadism in our study. However, we did not find
a difference in hypogonadism prevalence or COVID-19 hospitalization risk among cohorts with
testosterone measurements available before or after COVID-19. In addition, COVID-19 infection did
not result in a permanent lowering of testosterone, thyroid, or cortisol concentrations in prior
studies.40,41 Unbound testosterone concentrations were either not available or were measured by
inaccurate methods for most patients. Total testosterone concentrations were not always measured
by mass spectrometry.21,42 Ideally, the diagnosis of hypogonadism requires 2 subnormal testosterone
measurements because of the day-to-day variation in testosterone concentrations.42 However, the
probability of a change in either direction with repeated measurements is statistically equal.
Therefore, while repeated measurements are important for the diagnosis of hypogonadism in a given
patient, most epidemiologic or cross-sectional studies rely on a single measure of testosterone
concentration.23 Therefore, we used a single measure of testosterone conentration to document the
adequacy of TTh, as previously described.26 Although it is possible that some men with eugonadism
were included in the group with hypogonadism, such misclassification would have led to a type II
error (false-negative result). Hence, the availability of 2 measures of testosterone concentration
would have likely amplified the differences in hospitalization among the men with hypogonadism
and those with eugonadism.

Conclusions
The findings of this cohort study suggest that men with hypogonadism are more likely than men with
eugonadism to be hospitalized after COVID-19 infection. They also suggest that men with
hypogonadism who receive adequate TTh to achieve normal testosterone concentrations have a
reduction in the risk of COVID-19–related hospitalization. Prospective clinical trials are needed to
explore the efficacy of TTh in preventing hospitalizations after COVID-19 and similar respiratory
illnesses among men with hypogonadism.
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